Metabolic Glycoengineering Sensitizes Drug-Resistant Pancreatic Cancer Cells to Tyrosine Kinase Inhibitors Erlotinib and Gefitinib

Metastatic human pancreatic cancer cells (the SW1990 line) that are resistant to the EGFR-targeting tyrosine kinase inhibitor drugs (TKI) erlotinib and gefitinib were treated with 1,3,4-O-Bu(3)ManNAc, a “metabolic glycoengineering” drug candidate that increased sialylation by ∼12-fold. Consistent wi...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Bioorg Med Chem Lett
Main Authors: Mathew, Mohit P., Tan, Elaine, Saeui, Christopher T., Bovonratwet, Patawut, Liu, Lingshu, Bhattacharya, Rahul, Yarema, Kevin J.
Formáid: Artigo
Teanga:Inglês
Foilsithe: 2015
Ábhair:
Article
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5753412/
https://ncbi.nlm.nih.gov/pubmed/25690786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bmcl.2015.01.060
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla